AcelRx Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRX Nasdaq 2834 http://www.acelrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference - May 20th, 2022 4:49 pm
Why AcelRx Pharma Shares Are Trading Higher Today? - May 19th, 2022 3:56 pm
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® - May 19th, 2022 12:30 pm
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates - May 16th, 2022 12:45 pm
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update - May 16th, 2022 11:30 am
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2022 9:35 pm
Organogenesis (ORGO) Q1 Earnings Lag Estimates - May 10th, 2022 9:35 pm
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia - May 10th, 2022 12:30 pm
AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 - May 9th, 2022 11:30 pm
AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program - Apr 27th, 2022 12:00 pm
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 - Apr 25th, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 - Apr 21st, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures - Mar 31st, 2022 8:10 pm
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit - Mar 29th, 2022 5:08 pm
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates - Mar 10th, 2022 10:15 pm
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Mar 10th, 2022 9:01 pm
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 - Mar 3rd, 2022 9:05 pm
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures - Feb 1st, 2022 1:30 pm
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? - Jan 31st, 2022 9:24 am
Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... - Jan 27th, 2022 6:38 pm